pI: 8.5374 |
Length (AA): 324 |
MW (Da): 36443 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 3
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | ME49 merozoite. | Hehl AB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 Oocyst, ME49 Bradyzoite. | Gregory Fritz HM Sibley/Greg |
Sibley/Greg | ToxoDB |
Gregory | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Ortholog group members (OG5_128852)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G38050 | probable steroid reductase DET2 |
Brugia malayi | Bm1_06570 | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 |
Caenorhabditis elegans | CELE_F42F12.3 | Protein F42F12.3 |
Caenorhabditis elegans | CELE_F19H6.4 | Protein F19H6.4 |
Entamoeba histolytica | EHI_197070 | steroid 5-alpha reductase, putative |
Homo sapiens | ENSG00000145545 | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) |
Homo sapiens | 6716 | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) |
Leishmania braziliensis | LbrM.17.1210 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein |
Leishmania donovani | LdBPK_171200.1 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein |
Leishmania infantum | LinJ.17.1200 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein |
Leishmania major | LmjF.17.1100 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein |
Leishmania mexicana | LmxM.17.1100 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like protein |
Loa Loa (eye worm) | LOAG_07203 | hypothetical protein |
Mus musculus | ENSMUSG00000021594 | steroid 5 alpha-reductase 1 |
Mus musculus | ENSMUSG00000038541 | steroid 5 alpha-reductase 2 |
Mycobacterium ulcerans | MUL_3208 | hypothetical protein |
Oryza sativa | 9272051 | Os11g0184100 |
Oryza sativa | 4324809 | Os01g0851600 |
Schmidtea mediterranea | mk4.000630.02 | 3-oxo-5-alpha-steroid 4-dehydrogenase 1 |
Schmidtea mediterranea | mk4.000630.01 | |
Trypanosoma brucei gambiense | Tbg972.8.1930 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative |
Trypanosoma brucei | Tb927.8.2480 | 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative |
Trypanosoma cruzi | TcCLB.509331.70 | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative |
Trypanosoma cruzi | TcCLB.504427.70 | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative |
Toxoplasma gondii | TGME49_304480 | 3-oxo-5-alpha-steroid 4-dehydrogenase |
Trichomonas vaginalis | TVAG_146690 | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative |
Trichomonas vaginalis | TVAG_391520 | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative |
Trichomonas vaginalis | TVAG_096490 | 3-oxo-5-alpha-steroid 4-dehydrogenase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.2480 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.2480 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.2480 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.2480 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F19H6.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
TGME49_304480 this record | Toxoplasma gondii | Probably non-essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.8
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Rattus norvegicus | Steroid 5-alpha-reductase 1 | Compounds | References |
Rattus norvegicus | Steroid 5-alpha-reductase 2 | Compounds | References |
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) | Compounds | References |
Homo sapiens | steroid-5-alpha-reductase, alpha polypeptide 2 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 2) | Compounds | References |
Species | Target | Length | Identity | Alignment span | Linked Drugs | Reference |
---|---|---|---|---|---|---|
Rattus norvegicus | Steroid 5-alpha-reductase | 254 aa | 36.1% | 255 aa | Compounds | References |